| Autor: |
Hayakawa, Jin, Kanda, Junya, Akahoshi, Yu, Harada, Naonori, Kameda, Kazuaki, Ugai, Tomotaka, Wada, Hidenori, Ishihara, Yuko, Kawamura, Koji, Sakamoto, Kana, Ashizawa, Masahiro, Sato, Miki, Terasako-Saito, Kiriko, Kimura, Shun-ichi, Kikuchi, Misato, Yamazaki, Rie, Kako, Shinichi, Kanda, Yoshinobu |
| Zdroj: |
International Journal of Hematology; May2017, Vol. 105 Issue 5, p578-586, 9p |
| Abstrakt: |
Aplastic anemia patients who received rabbit antithymocyte globulin exhibited response and survival rates inferior to those who received horse antithymocyte globulin in several studies. Therefore, we conducted a meta-analysis to compare rabbit and horse antithymocyte globulin as immunosuppressive therapy for aplastic anemia. We searched online databases for studies that compared antithymocyte globulin regimens as first-line treatment for aplastic anemia, including both randomized and non-randomized controlled trials. The early mortality rate at 3 months and overall response rate at 6 months were evaluated. Thirteen studies were included in the analysis. The risk ratio (RR) of early mortality for rabbit vs. horse antithymocyte globulin was 1.33 [95% confidence interval (CI) 0.69-2.57; P = 0.39], with significant heterogeneity. A sensitivity analysis suggested higher early mortality rate in patients who received rabbit antithymocyte globulin. The overall response rate was significantly higher in patients who received horse antithymocyte globulin (RR 1.27; 95% CI 1.05-1.54; P = 0.015). In conclusion, in aplastic anemia patients treated with ATG, early mortality rate was not significantly different in patients receiving horse or rabbit ATG, although a sensitivity analysis showed higher early mortality in the rabbit ATG group. Horse ATG was associated with significantly higher response rate than rabbit ATG. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink